Hansoh Pharma's Fosaprepitant Dimeglumine for Injection (Tanneng) Approved as China's First Domestic Product

Source:PharmaCube Info

On October 15, Hansoh Pharma announced that its subsidiary, Hengrui Medicine’s “Fosaprepitant Dimeglumine for Injection” (trade name: Tanneng) has received approval from the National Medical Products Administration (NMPA) for market launch.

As a drug in urgent clinical need, fosaprepitant dimeglumine has been included in China’s “First Batch of Encouraged Generic Drug List.” The announcement indicates that Tanneng is the first and currently only approved fosaprepitant dimeglumine product in China. It was submitted under Category 3 of new chemical drugs and is deemed to have passed the consistency evaluation.

Fosaprepitant Structural Formula

Fosaprepitant is a prodrug of aprepitant that undergoes rapid hydrolysis in vivo to be metabolized into aprepitant. It is another NK-1 receptor antagonist approved for clinical use following aprepitant, primarily indicated for the prevention and treatment of acute and delayed nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy, including initial or repeated administration of high-dose cisplatin. The originator company is Merck & Co., which first received approval in the European Union on January 10, 2008, followed by approvals in the United States and Japan. However, it has not yet been marketed in China.